Pharmaceutical

IMIDomics to license TNAX’s drug candidate for IMIDs

IMIDomics has entered an agreement to license TNAX Biopharma’s IMB1001 to treat immune-mediated inflammatory diseases (IMIDs).

Sep 7, 2023 - 20:00
IMIDomics to license TNAX’s drug candidate for IMIDs
IMIDomics has entered an agreement to license TNAX Biopharma’s IMB1001 to treat immune-mediated inflammatory diseases (IMIDs).
Read the original article

Tags:

Previous Article

Veracyte and Gustave Roussy announce partnership for cancer therapies

Next Article

Novo Nordisk and Broad Institute to explore drug targets for diabetes, CMDs 

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

UI-059 by Korea United Pharm for Reflux Esophagitis (Ga...

Dec 20, 2023

BMS reports 2% revenue loss in 2023 after Revlimid generics hurt sales

BMS reports 2% revenue loss in 2023 after Revlimid gene...

Feb 2, 2024

EMA CHMP provides positive opinion for ViiV’s cabotegravir

EMA CHMP provides positive opinion for ViiV’s cabotegravir

Jul 25, 2023